# GQ Bio Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gq-bio-therapeutics

- Industry: Biotechnology
- Headquarters: Hamburg, Germany
- Website: www.gq-biotx.com/
- Total disclosed funding: $6.4M
- Latest round: Series A (Oct 22, 2020)
- Investors on record: 5

## About

GQ Bio Therapeutics GmbH focuses on innovative gene therapy solutions through its advanced gene therapy vector platform, targeting chronic conditions to improve patient health outcomes.GQ Bio Therapeutics GmbH is engaged in developing gene therapies, specifically utilizing a high-capacity adenovirus vector platform. The company, founded in 2012 in Hamburg, Germany, has completed 4 significant deals and is on track for its most recent deal on February 27, 2025. The firm was established by industry experts, and it has successfully raised a total of USD 5.40 mn. It has a recent pivotal event where Pacira Pharmaceuticals, Inc. agreed to acquire 81% of GQ Bio from various investors for approximately USD 32 mn.GQ Bio specializes in pioneering gene therapy solutions through its high-capacity gene therapy vector platform, designed for the efficient delivery of large and multiple genes. This platform underpins the development of transformative medicines targeting chronic and prevalent conditions such as osteoarthritis and intervertebral disc degeneration. GQ Bio's innovative products primarily serve healthcare providers and research institutions focused on advancing patient outcomes in genetic medicine. The company aims to enhance the health and quality of life for patients by providing one-time gene therapy treatments, catering to an international market that includes North America and Europe, where there is a significant demand for advanced therapeutic options.GQ Bio's revenue model revolves around the development and commercialization of its gene therapy products, which includes partnerships with pharmaceutical companies and healthcare institutions to facilitate access to its innovative therapies. The firm engages in direct-to-consumer transactions while also establishing B2B relationships with hospitals and clinical research organizations. The transaction structure typically involves licensing agreements, where clients may gain rights to utilize GQ Bio’s proprietary vector technology in their own therapeutic developments. Specific pricing plans are tailored to the nature of the collaborations, focusing on the value of the gene therapies provided, including any flagship products that signify GQ Bio's commitment to innovation in the gene therapy space.In February 2025, GQ Bio plans to leverage the acquisition by Pacira BioSciences to further integrate its high-capacity adenovirus gene therapy vector platform, enhancing its portfolio in the development of genetic medicines targeting musculoskeletal diseases. The company is focused on launching new gene therapy products aimed at chronic conditions, with plans to expand its market presence in North America and Europe by 2026. The recent funding from the acquisition will be utilized to support these strategic initiatives and to advance their research and development efforts.

## Funding rounds

- Series A, Oct 22, 2020, $6.4M — High-Tech Gruenderfonds, Pacira Pharmaceuticals, Inc., Noshaq, SAMUM Vermögensverwaltungs GmbH
- Seed, Nov 12, 2012 — High-Tech Gruenderfonds, Innovationsstarter Fonds Hamburg

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed, Series A
- Innovationsstarter Fonds Hamburg (https://capitalatlas.ai/funds/innovationsstarter-fonds-hamburg) — Seed
- Pacira Pharmaceuticals, Inc. — Series A
- Noshaq (https://capitalatlas.ai/funds/noshaq) — Series A
- SAMUM Vermögensverwaltungs GmbH — Series A